The fact that FPR1 is abundantly expressed in gliomas and other cancer cells in combination with the observation that activation of FPR1 stimulates receptor-mediated endocytosis34–36, makes it a highly attractive target for radiopharmaceutical development. Here, FPR1 is linked to cancer.